All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

fampridine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4163	504-24-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: fampyra dalfampridine ampyra pyridin-4-amine 4-aminopyridine fampridine	One of the POTASSIUM CHANNEL BLOCKERS with secondary effect on calcium currents which is used mainly as a research tool and to characterize channel subtypes. Molecular weight: 94.12 Formula: C5H6N2 CLOGP: 0.32 LIPINSKI: 0 HAC: 2 HDO: 1 TPSA: 38.91 ALOGS: 0.46 ROTB: 0

Drug dosage:

Dose	Unit	Route
20	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	90.30 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	3.04 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	2.60 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	9.30 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	1 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	3.60 hours	Lombardo F, Berellini G, Obach RS
S (Water solubility)	112 mg/mL	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
Jan. 22, 2010	FDA	ACORDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Multiple sclerosis relapse	1963.23	14.64	831	38658	47647	63401886
Urinary tract infection	1451.44	14.64	1244	38245	263440	63186093
Laboratory test abnormal	1010.84	14.64	438	39051	26474	63423059
Balance disorder	767.03	14.64	537	38952	83885	63365648
Multiple sclerosis	730.90	14.64	339	39150	24033	63425500
Fall	706.66	14.64	1031	38458	391303	63058230
Gait disturbance	617.11	14.64	660	38829	182518	63267015
Urine analysis abnormal	598.43	14.64	191	39298	4825	63444708
Therapy cessation	502.05	14.64	283	39206	30174	63419359
Muscular weakness	408.10	14.64	439	39050	121914	63327619
Seizure	336.10	14.64	413	39076	132221	63317312
Muscle spasticity	241.38	14.64	157	39332	21637	63427896
Peroneal nerve palsy	225.82	14.64	92	39397	4743	63444790
Escherichia urinary tract infection	221.27	14.64	120	39369	11842	63437691
Insomnia	217.40	14.64	439	39050	214813	63234720
Lymphocyte count decreased	188.77	14.64	154	39335	30103	63419430
Central nervous system lesion	170.20	14.64	97	39392	10538	63438995
Gait inability	165.76	14.64	184	39305	52775	63396758
B-lymphocyte count decreased	161.27	14.64	49	39440	1045	63448488
Secondary progressive multiple sclerosis	160.59	14.64	52	39437	1375	63448158
Flushing	155.76	14.64	212	39277	74875	63374658
Dizziness	154.54	14.64	601	38888	429324	63020209
Memory impairment	148.60	14.64	247	39242	104011	63345522
Rheumatoid arthritis	139.47	14.64	4	39485	253815	63195718
Therapeutic response unexpected	137.48	14.64	105	39384	18654	63430879
Asthenia	136.73	14.64	535	38954	383069	63066464
Hypoaesthesia	134.95	14.64	313	39176	168080	63281453
Culture urine positive	131.70	14.64	58	39431	3629	63445904
Off label use	125.76	14.64	141	39348	674321	62775212
Micturition urgency	118.22	14.64	74	39415	9537	63439996
Paraesthesia	117.32	14.64	284	39205	156682	63292851
Systemic lupus erythematosus	115.84	14.64	3	39486	208915	63240618
Pollakiuria	114.19	14.64	112	39377	27825	63421708
Inappropriate schedule of product administration	111.90	14.64	218	39271	103747	63345786
Urine leukocyte esterase positive	110.97	14.64	51	39438	3528	63446005
Drug ineffective	110.68	14.64	1060	38429	1043705	62405828
Lymphopenia	109.52	14.64	91	39398	18236	63431297
Toxicity to various agents	106.48	14.64	14	39475	247236	63202297
Trigeminal neuralgia	105.53	14.64	49	39440	3470	63446063
Urinary incontinence	104.94	14.64	114	39375	31900	63417633
Product substitution issue	103.09	14.64	83	39406	15913	63433620
Dyspnoea	101.06	14.64	160	39329	661153	62788380
Head injury	97.65	14.64	102	39387	27294	63422239
Depression	96.57	14.64	305	39184	196187	63253346
JC polyomavirus test positive	93.90	14.64	35	39454	1418	63448115
Mobility decreased	91.33	14.64	220	39269	120939	63328594
Joint swelling	89.65	14.64	46	39443	327620	63121913
Glossodynia	87.88	14.64	6	39483	178870	63270663
Hand deformity	85.80	14.64	3	39486	159454	63290079
Neurogenic bladder	81.04	14.64	40	39449	3245	63446288
Anaemia	80.54	14.64	41	39448	293389	63156144
T-lymphocyte count increased	80.52	14.64	18	39471	104	63449429
Dysstasia	79.39	14.64	81	39408	21085	63428448
Bladder disorder	76.60	14.64	55	39434	8891	63440642
CD4 lymphocytes increased	75.89	14.64	18	39471	140	63449393
Infusion related reaction	75.73	14.64	29	39460	245492	63204041
Completed suicide	74.22	14.64	4	39485	145669	63303864
Exposure during pregnancy	74.17	14.64	6	39483	155541	63293992
T-lymphocyte count decreased	72.65	14.64	20	39469	296	63449237
Product use issue	71.49	14.64	24	39465	220496	63229037
Influenza like illness	70.49	14.64	139	39350	66685	63382848
Contraindicated product administered	70.01	14.64	24	39465	217624	63231909
Motor dysfunction	67.57	14.64	55	39434	10706	63438827
Progressive multiple sclerosis	67.54	14.64	26	39463	1152	63448381
Wound	66.20	14.64	11	39478	163252	63286281
Treatment failure	65.68	14.64	21	39468	199022	63250511
Arthralgia	65.24	14.64	163	39326	569547	62879986
Maternal exposure during pregnancy	64.59	14.64	28	39461	220034	63229499
Dysgraphia	64.04	14.64	34	39455	3212	63446321
Movement disorder	63.87	14.64	73	39416	21588	63427945
Walking aid user	63.58	14.64	53	39436	10664	63438869
CD4 lymphocytes decreased	62.71	14.64	26	39463	1401	63448132
Red blood cells urine positive	62.40	14.64	33	39456	3093	63446440
Acute kidney injury	60.87	14.64	45	39444	263370	63186163
Loss of control of legs	59.88	14.64	25	39464	1371	63448162
White blood cells urine positive	59.16	14.64	38	39451	5120	63444413
Arthropathy	58.39	14.64	37	39452	234755	63214778
Lower respiratory tract infection	58.11	14.64	7	39482	132300	63317233
Neutropenia	56.79	14.64	19	39470	174986	63274547
Muscle spasms	56.38	14.64	219	39270	155931	63293602
Gait spastic	56.28	14.64	16	39473	268	63449265
Feeling abnormal	55.94	14.64	211	39278	148181	63301352
Primary progressive multiple sclerosis	54.82	14.64	13	39476	101	63449432
CD8 lymphocytes decreased	54.68	14.64	14	39475	154	63449379
Sinusitis	54.62	14.64	37	39452	226616	63222917
Temperature intolerance	54.57	14.64	45	39444	8919	63440614
Product dose omission issue	53.48	14.64	287	39202	234026	63215507
Optic neuritis	52.72	14.64	43	39446	8392	63441141
Febrile neutropenia	52.68	14.64	6	39483	118443	63331090
Rash	52.13	14.64	177	39312	560694	62888839
Hemiparesis	50.15	14.64	67	39422	23215	63426318
Ataxia	49.59	14.64	54	39435	15141	63434392
Swelling	49.56	14.64	59	39430	275319	63174214
Drug intolerance	49.55	14.64	72	39417	308589	63140944
Epilepsy	49.51	14.64	72	39417	26993	63422540
Progressive multifocal leukoencephalopathy	49.30	14.64	50	39439	12921	63436612
Lymphocyte count abnormal	49.06	14.64	18	39471	697	63448836
Magnetic resonance imaging abnormal	48.98	14.64	28	39461	3057	63446476
Tremor	48.16	14.64	186	39303	132053	63317480
Burning sensation	47.80	14.64	105	39384	54302	63395231
Ankle fracture	47.36	14.64	57	39432	17798	63431735
Dysuria	46.76	14.64	79	39410	33659	63415874
Haemoglobin urine present	46.60	14.64	18	39471	805	63448728
Hypotension	46.34	14.64	61	39428	272543	63176990
Psoriatic arthropathy	45.13	14.64	3	39486	91517	63358016
Stomatitis	45.11	14.64	15	39474	138710	63310823
Urine abnormality	44.33	14.64	36	39453	6983	63442550
Diarrhoea	44.08	14.64	263	39226	715103	62734430
Blister	44.06	14.64	13	39476	129801	63319732
Product use in unapproved indication	43.45	14.64	29	39460	179051	63270482
Invasive ductal breast carcinoma	42.50	14.64	35	39454	6923	63442610
COVID-19	41.93	14.64	160	39329	112943	63336590
Escherichia test positive	41.55	14.64	23	39466	2361	63447172
Relapsing-remitting multiple sclerosis	41.03	14.64	15	39474	575	63448958
Extra dose administered	41.02	14.64	33	39456	6317	63443216
Status epilepticus	41.01	14.64	49	39440	15184	63434349
Musculoskeletal disorder	40.82	14.64	57	39432	20587	63428946
Pain	39.69	14.64	284	39205	740344	62709189
Nitrite urine present	38.82	14.64	17	39472	1049	63448484
Urine odour abnormal	38.74	14.64	32	39457	6357	63443176
Weight increased	36.98	14.64	66	39423	260726	63188807
Wheelchair user	36.96	14.64	31	39458	6288	63443245
Hip fracture	36.91	14.64	66	39423	29408	63420125
Blood immunoglobulin M decreased	36.77	14.64	16	39473	972	63448561
Cognitive disorder	36.41	14.64	96	39393	55719	63393814
Hypokinesia	36.16	14.64	44	39445	13892	63435641
Urinary tract infection pseudomonal	35.66	14.64	15	39474	838	63448695
General symptom	35.49	14.64	22	39467	2786	63446747
Generalised tonic-clonic seizure	35.09	14.64	64	39425	28952	63420581
Abdominal pain	35.04	14.64	82	39407	293374	63156159
Vitamin B12 increased	34.74	14.64	16	39473	1112	63448421
Drug hypersensitivity	34.61	14.64	90	39399	310597	63138936
Cystitis	34.27	14.64	93	39396	54898	63394635
Pancytopenia	34.21	14.64	9	39480	96924	63352609
Pleural effusion	34.16	14.64	8	39481	93202	63356331
Gastrointestinal haemorrhage	33.96	14.64	5	39484	81171	63368362
Urinary tract infection bacterial	33.90	14.64	27	39462	5095	63444438
Vomiting	33.75	14.64	207	39282	559410	62890123
Acute disseminated encephalomyelitis	33.42	14.64	10	39479	202	63449331
Drug interaction	33.37	14.64	57	39432	229074	63220459
Folliculitis	32.72	14.64	3	39486	70314	63379219
Therapy interrupted	32.40	14.64	66	39423	32389	63417144
Breast cancer	32.36	14.64	84	39405	48299	63401234
Sensory disturbance	32.01	14.64	41	39448	13631	63435902
Pneumonia	31.86	14.64	161	39328	456606	62992927
Lymphocyte percentage decreased	31.80	14.64	21	39468	2964	63446569
Limb discomfort	31.55	14.64	62	39427	29654	63419879
Adverse drug reaction	31.39	14.64	115	39374	79599	63369934
General physical health deterioration	30.35	14.64	49	39440	201353	63248180
Tongue biting	30.21	14.64	16	39473	1504	63448029
Muscle tightness	29.95	14.64	37	39452	11863	63437670
B-lymphocyte count abnormal	29.01	14.64	7	39482	59	63449474
Incontinence	29.01	14.64	36	39453	11596	63437937
Fatigue	28.94	14.64	739	38750	887289	62562244
Bacterial test positive	28.92	14.64	25	39464	5282	63444251
Glycosylated haemoglobin increased	28.75	14.64	37	39452	12361	63437172
Coordination abnormal	28.69	14.64	39	39450	13734	63435799
Decreased appetite	28.50	14.64	72	39417	250980	63198553
Respiratory failure	28.25	14.64	14	39475	101844	63347689
Hepatic enzyme increased	27.96	14.64	52	39437	202276	63247257
Platelet count decreased	27.89	14.64	19	39470	116103	63333430
Blood thyroid stimulating hormone decreased	27.85	14.64	23	39466	4567	63444966
Speech disorder	27.64	14.64	71	39418	40558	63408975
Thrombocytopenia	27.58	14.64	32	39457	151125	63298408
Fibromyalgia	27.38	14.64	8	39481	80412	63369121
Infection	27.37	14.64	64	39425	229109	63220424
Hypersensitivity	27.36	14.64	92	39397	292593	63156940
Impaired healing	27.10	14.64	15	39474	102527	63347006
Diplopia	27.02	14.64	51	39438	23677	63425856
Paraparesis	26.87	14.64	17	39472	2231	63447302
Asthma	26.68	14.64	24	39465	127537	63321996
Stress	26.53	14.64	97	39392	67070	63382463
Back pain	26.11	14.64	265	39224	263880	63185653
Urinary retention	26.06	14.64	58	39431	30243	63419290
Immune reconstitution inflammatory syndrome	25.99	14.64	25	39464	6059	63443474
Discomfort	25.90	14.64	40	39449	167334	63282199
Protein urine present	25.87	14.64	25	39464	6095	63443438
Decreased interest	25.58	14.64	19	39470	3235	63446298
Vitamin D deficiency	25.47	14.64	37	39452	13855	63435678
Invasive lobular breast carcinoma	25.41	14.64	12	39477	883	63448650
Urine ketone body present	25.20	14.64	17	39472	2486	63447047
Headache	24.86	14.64	541	38948	632700	62816833
Pyrexia	24.83	14.64	181	39308	470297	62979236
Urinary sediment present	24.70	14.64	16	39473	2187	63447346
Cardiac arrest	23.79	14.64	14	39475	92531	63357002
Intentional product use issue	23.41	14.64	27	39462	127865	63321668
Oxygen saturation decreased	23.35	14.64	13	39476	88572	63360961
Therapeutic product effect incomplete	23.33	14.64	26	39463	125030	63324503
Lymphocyte percentage abnormal	22.81	14.64	5	39484	26	63449507
Psoriasis	22.57	14.64	13	39476	86944	63362589
Intentional overdose	22.43	14.64	9	39480	74143	63375390
Hyponatraemia	22.29	14.64	22	39467	111878	63337655
Urge incontinence	22.23	14.64	11	39478	897	63448636
Irritable bowel syndrome	21.86	14.64	12	39477	82400	63367133
Urinary tract infection enterococcal	21.68	14.64	16	39473	2697	63446836
Peripheral swelling	21.32	14.64	89	39400	265853	63183680
Skin laceration	21.28	14.64	45	39444	22663	63426870
Hyperkalaemia	21.20	14.64	4	39485	54199	63395334
Wheezing	21.20	14.64	17	39472	95578	63353955
Cystitis klebsiella	20.68	14.64	7	39482	213	63449320
Dysarthria	20.65	14.64	66	39423	42645	63406888
Rectal haemorrhage	20.55	14.64	3	39486	49027	63400506
Urinary tract disorder	20.53	14.64	16	39473	2925	63446608
Human papilloma virus test positive	20.39	14.64	9	39480	566	63448967
Overdose	20.31	14.64	25	39464	115053	63334480
Initial insomnia	20.30	14.64	22	39467	6135	63443398
Hypoxia	20.26	14.64	6	39483	59786	63389747
Red blood cell count abnormal	20.20	14.64	11	39478	1093	63448440
Vertigo	19.20	14.64	81	39408	59806	63389727
International normalised ratio increased	19.09	14.64	3	39486	46422	63403111
Proteus test positive	19.06	14.64	7	39482	272	63449261
Inflammation	19.04	14.64	14	39475	82259	63367274
Visual impairment	18.92	14.64	103	39386	84343	63365190
Type 2 diabetes mellitus	18.92	14.64	8	39481	63860	63385673
Haematochezia	18.83	14.64	5	39484	53539	63395994
Anaphylactic reaction	18.45	14.64	9	39480	66091	63383442
Feeling hot	18.45	14.64	71	39418	50283	63399250
Depressed mood	18.43	14.64	61	39428	40130	63409403
Neutrophil percentage increased	18.39	14.64	15	39474	2928	63446605
Intraductal proliferative breast lesion	18.38	14.64	15	39474	2930	63446603
Metabolic acidosis	18.34	14.64	3	39486	45066	63404467
Contraindicated product prescribed	18.33	14.64	11	39478	1314	63448219
Prescribed underdose	18.28	14.64	50	39439	29639	63419894
Lymphocyte count increased	18.26	14.64	16	39473	3442	63446091
Therapeutic response changed	17.99	14.64	10	39479	1035	63448498
Hypertonic bladder	17.75	14.64	16	39473	3572	63445961
Living in residential institution	17.70	14.64	8	39481	532	63449001
Urosepsis	17.70	14.64	37	39452	18487	63431046
Arthritis	17.64	14.64	28	39461	115893	63333640
Blood pressure systolic increased	17.50	14.64	4	39485	47393	63402140
C-reactive protein increased	17.32	14.64	20	39469	94687	63354846
CD4 lymphocyte percentage decreased	17.07	14.64	3	39486	3	63449530
Urinary tract infection staphylococcal	17.06	14.64	7	39482	367	63449166
Hypoglycaemia	17.04	14.64	8	39481	60057	63389476
Vitamin D decreased	16.94	14.64	26	39463	10216	63439317
Bacterial test	16.90	14.64	10	39479	1164	63448369
Postictal paralysis	16.76	14.64	5	39484	100	63449433
Haematocrit abnormal	16.68	14.64	9	39480	878	63448655
Tachycardia	16.64	14.64	30	39459	118126	63331407
Focal dyscognitive seizures	16.41	14.64	14	39475	2907	63446626
Cardiac failure congestive	16.39	14.64	20	39469	92413	63357120
Bladder dysfunction	16.25	14.64	9	39480	925	63448608
Cardiac failure	16.11	14.64	19	39470	89123	63360410
Eye contusion	16.09	14.64	12	39477	2055	63447478
B-lymphocyte count increased	16.02	14.64	5	39484	117	63449416
Aphasia	15.96	14.64	51	39438	32949	63416584
Bone pain	15.94	14.64	7	39482	54634	63394899
Neutrophil count increased	15.78	14.64	33	39456	16494	63433039
Injection site scar	15.52	14.64	9	39480	1009	63448524
Citrobacter infection	15.48	14.64	7	39482	466	63449067
Pulmonary fibrosis	15.44	14.64	3	39486	39806	63409727
Multiple organ dysfunction syndrome	15.43	14.64	8	39481	56744	63392789
Glucose urine present	15.39	14.64	8	39481	724	63448809
Insurance issue	15.35	14.64	19	39470	6102	63443431
Postictal state	15.32	14.64	9	39480	1034	63448499
Lower limb fracture	15.12	14.64	41	39448	24180	63425353
Transferrin saturation decreased	14.99	14.64	8	39481	764	63448769
White blood cell count decreased	14.91	14.64	142	39347	138962	63310571
Impaired self-care	14.88	14.64	11	39478	1859	63447674
Intervertebral disc protrusion	14.67	14.64	40	39449	23669	63425864

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Multiple sclerosis relapse	1000.45	20.70	318	13452	12815	34930346
Multiple sclerosis	464.73	20.70	151	13619	6494	34936667
Balance disorder	332.41	20.70	204	13566	40450	34902711
Gait disturbance	307.90	20.70	260	13510	84880	34858281
Laboratory test abnormal	300.78	20.70	151	13619	20240	34922921
Urinary tract infection	296.30	20.70	253	13517	83828	34859333
Fall	287.84	20.70	375	13395	202510	34740651
Muscle spasticity	275.29	20.70	99	13671	5789	34937372
Drug ineffective	179.31	20.70	485	13285	456266	34486895
Relapsing-remitting multiple sclerosis	166.51	20.70	45	13725	1005	34942156
Muscular weakness	161.77	20.70	170	13600	72727	34870434
Central nervous system lesion	158.08	20.70	68	13702	6395	34936766
Gait spastic	155.35	20.70	43	13727	1053	34942108
Mobility decreased	147.15	20.70	110	13660	30018	34913143
Insomnia	137.28	20.70	186	13584	103721	34839440
Needle fatigue	136.16	20.70	37	13733	844	34942317
Movement disorder	127.60	20.70	72	13698	12176	34930985
Therapy cessation	122.96	20.70	79	13691	16894	34926267
Ataxia	116.79	20.70	71	13699	13782	34929379
Memory impairment	114.24	20.70	111	13659	43207	34899954
Hypertonic bladder	108.82	20.70	37	13733	1827	34941334
Micturition urgency	107.04	20.70	52	13718	6473	34936688
Monoparesis	100.50	20.70	37	13733	2309	34940852
Seizure	98.49	20.70	160	13610	104697	34838464
B-lymphocyte count decreased	94.69	20.70	26	13744	617	34942544
Secondary progressive multiple sclerosis	92.20	20.70	23	13747	370	34942791
Pollakiuria	89.75	20.70	69	13701	19605	34923556
Gait inability	84.35	20.70	68	13702	20690	34922471
Peroneal nerve palsy	77.98	20.70	33	13737	2978	34940183
Hypoaesthesia	75.00	20.70	106	13664	61338	34881823
Flushing	67.16	20.70	73	13697	32347	34910814
JC polyomavirus test positive	66.06	20.70	20	13750	677	34942484
Product substitution issue	63.41	20.70	43	13727	10052	34933109
Acute kidney injury	62.87	20.70	21	13749	304967	34638194
Trigeminal neuralgia	62.46	20.70	22	13748	1207	34941954
Therapeutic response unexpected	62.33	20.70	42	13728	9715	34933446
Anaemia	59.98	20.70	10	13760	233325	34709836
Dizziness	57.74	20.70	203	13567	218318	34724843
Progressive multifocal leukoencephalopathy	57.57	20.70	40	13730	9724	34933437
Nocturia	55.95	20.70	40	13730	10170	34932991
Influenza like illness	55.11	20.70	61	13709	27573	34915588
Hypotension	51.70	20.70	12	13758	221637	34721524
Dysarthria	51.56	20.70	66	13704	34716	34908445
Lymphocyte count decreased	48.70	20.70	52	13718	22570	34920591
Asthenia	48.57	20.70	208	13562	245043	34698118
Progressive multiple sclerosis	44.96	20.70	12	13758	255	34942906
Paraesthesia	44.71	20.70	86	13684	64086	34879075
Toxicity to various agents	44.49	20.70	12	13758	200350	34742811
Off label use	43.86	20.70	61	13709	419463	34523698
Dyspnoea	41.18	20.70	53	13717	376729	34566432
COVID-19	40.12	20.70	92	13678	77458	34865703
Neutropenia	39.63	20.70	7	13763	156771	34786390
Drug interaction	39.32	20.70	20	13750	225926	34717235
Erectile dysfunction	38.48	20.70	44	13726	20593	34922568
Urinary incontinence	38.20	20.70	42	13728	18832	34924329
Lymphocyte percentage decreased	38.02	20.70	18	13752	2114	34941047
Neurogenic bladder	37.61	20.70	17	13753	1796	34941365
Urine analysis abnormal	36.01	20.70	17	13753	1984	34941177
Muscle spasms	34.48	20.70	85	13685	74916	34868245
T-lymphocyte count decreased	33.17	20.70	9	13761	204	34942957
White blood cells urine positive	32.92	20.70	14	13756	1278	34941883
Decreased vibratory sense	31.79	20.70	10	13760	385	34942776
Cystitis	31.45	20.70	28	13742	9737	34933424
Paraparesis	30.81	20.70	15	13755	1874	34941287
Bladder disorder	30.60	20.70	18	13752	3286	34939875
Walking aid user	30.54	20.70	15	13755	1909	34941252
CD8 lymphocytes decreased	30.35	20.70	7	13763	79	34943082
Thrombocytopenia	30.02	20.70	12	13758	156235	34786926
Temperature intolerance	30.01	20.70	18	13752	3404	34939757
Cognitive disorder	29.91	20.70	46	13724	28647	34914514
Vitamin B12 increased	28.83	20.70	9	13761	338	34942823
Renal failure	28.61	20.70	8	13762	130549	34812612
Inappropriate schedule of product administration	27.99	20.70	70	13700	62226	34880935
Adverse drug reaction	26.42	20.70	44	13726	29298	34913863
Burning sensation	25.83	20.70	34	13736	18360	34924801
Fatigue	25.11	20.70	239	13531	370414	34572747
Diarrhoea	25.06	20.70	75	13695	389837	34553324
Musculoskeletal stiffness	24.80	20.70	56	13714	46624	34896537
Pancytopenia	24.57	20.70	4	13766	95153	34848008
Dysstasia	24.44	20.70	27	13743	12168	34930993
General symptom	23.93	20.70	10	13760	874	34942287
Herpes zoster	23.81	20.70	46	13724	34353	34908808
Platelet count decreased	23.31	20.70	9	13761	119708	34823453
Cardiac failure	23.20	20.70	4	13766	91244	34851917
Back pain	23.02	20.70	102	13668	121687	34821474
Motor dysfunction	22.46	20.70	20	13750	6954	34936207
Spinal cord injury cauda equina	21.48	20.70	6	13764	152	34943009
Depression	21.21	20.70	85	13685	97013	34846148
Somatosensory evoked potentials abnormal	21.01	20.70	6	13764	165	34942996
Generalised tonic-clonic seizure	20.75	20.70	33	13737	21141	34922020

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Multiple sclerosis relapse	2224.08	14.69	842	38428	45691	79659427
Urinary tract infection	1710.91	14.69	1263	38007	273249	79431869
Laboratory test abnormal	1616.92	14.69	583	38687	27465	79677653
Multiple sclerosis	737.87	14.69	310	38960	21972	79683146
Fall	710.62	14.69	1025	38245	486604	79218514
Balance disorder	674.14	14.69	482	38788	98375	79606743
Urine analysis abnormal	642.50	14.69	203	39067	6317	79698801
Gait disturbance	472.02	14.69	545	38725	206961	79498157
Muscular weakness	344.92	14.69	410	38860	160319	79544799
Muscle spasticity	343.98	14.69	181	39089	21294	79683824
Therapy cessation	343.74	14.69	220	39050	37342	79667776
B-lymphocyte count decreased	267.39	14.69	73	39197	1341	79703777
Seizure	266.13	14.69	392	38878	188442	79516676
Escherichia urinary tract infection	263.38	14.69	131	39139	13694	79691424
Central nervous system lesion	249.74	14.69	125	39145	13243	79691875
Peroneal nerve palsy	199.66	14.69	84	39186	5958	79699160
Gait spastic	195.10	14.69	55	39215	1142	79703976
Insomnia	193.70	14.69	394	38876	244776	79460342
Lymphocyte count decreased	187.53	14.69	168	39102	47121	79657997
Gait inability	181.51	14.69	182	39088	58735	79646383
Pollakiuria	181.43	14.69	149	39121	37168	79667950
Micturition urgency	181.22	14.69	99	39171	12542	79692576
Relapsing-remitting multiple sclerosis	177.87	14.69	54	39216	1465	79703653
Memory impairment	160.16	14.69	234	39036	111500	79593618
Secondary progressive multiple sclerosis	156.49	14.69	48	39222	1349	79703769
Culture urine positive	151.04	14.69	63	39207	4372	79700746
Movement disorder	149.88	14.69	117	39153	27142	79677976
Hypoaesthesia	141.24	14.69	288	38982	179064	79526054
Dizziness	134.04	14.69	563	38707	525878	79179240
Urine leukocyte esterase positive	132.25	14.69	56	39214	4035	79701083
Toxicity to various agents	130.10	14.69	25	39245	421515	79283603
Asthenia	123.11	14.69	538	38732	511151	79193967
Off label use	122.49	14.69	161	39109	907054	78798064
Therapeutic response unexpected	121.49	14.69	91	39179	19855	79685263
Needle fatigue	118.30	14.69	35	39235	867	79704251
Anaemia	116.76	14.69	37	39233	444978	79260140
Mobility decreased	115.47	14.69	212	39058	121963	79583155
Trigeminal neuralgia	115.33	14.69	49	39221	3560	79701558
Urinary incontinence	114.41	14.69	120	39150	40789	79664329
JC polyomavirus test positive	113.93	14.69	39	39231	1563	79703555
Acute kidney injury	107.83	14.69	61	39209	519343	79185775
Ataxia	107.32	14.69	93	39177	24946	79680172
T-lymphocyte count decreased	105.94	14.69	29	39241	538	79704580
T-lymphocyte count increased	102.40	14.69	21	39249	99	79705019
Progressive multifocal leukoencephalopathy	97.49	14.69	81	39189	20519	79684599
Flushing	97.42	14.69	164	39106	88104	79617014
Dyspnoea	96.46	14.69	172	39098	856853	78848265
Paraesthesia	96.29	14.69	245	39025	176078	79529040
Hypertonic bladder	95.68	14.69	45	39225	4156	79700962
White blood cells urine positive	93.83	14.69	50	39220	6025	79699093
Febrile neutropenia	93.28	14.69	5	39265	230994	79474124
COVID-19	92.31	14.69	225	39045	157449	79547669
Rheumatoid arthritis	89.19	14.69	3	39267	208467	79496651
Head injury	87.76	14.69	100	39170	37269	79667849
Monoparesis	87.40	14.69	40	39230	3471	79701647
CD8 lymphocytes decreased	85.52	14.69	21	39249	248	79704870
Lymphopenia	84.31	14.69	89	39181	30468	79674650
Neurogenic bladder	83.44	14.69	41	39229	4171	79700947
CD4 lymphocytes increased	83.39	14.69	21	39249	277	79704841
Product substitution issue	82.32	14.69	73	39197	20183	79684935
Neutropenia	80.78	14.69	21	39249	287689	79417429
Hypotension	78.78	14.69	61	39209	440256	79264862
Red blood cells urine positive	77.08	14.69	41	39229	4922	79700196
Completed suicide	76.98	14.69	14	39256	245753	79459365
Inappropriate schedule of product administration	72.21	14.69	185	39085	133443	79571675
Lymphocyte percentage decreased	68.64	14.69	38	39232	4938	79700180
Dysstasia	68.13	14.69	76	39194	27670	79677448
CD4 lymphocytes decreased	65.54	14.69	30	39240	2604	79702514
Influenza like illness	63.43	14.69	121	39149	71586	79633532
Drug interaction	61.84	14.69	68	39202	415115	79290003
Motor dysfunction	61.68	14.69	54	39216	14679	79690439
Bladder disorder	58.46	14.69	43	39227	9122	79695996
Dysuria	57.97	14.69	96	39174	50855	79654263
Vitamin B12 increased	57.94	14.69	22	39248	1191	79703927
Status epilepticus	57.08	14.69	66	39204	24975	79680143
Depression	56.60	14.69	234	39036	216556	79488562
Dysarthria	56.02	14.69	111	39159	67511	79637607
Joint swelling	55.49	14.69	37	39233	288609	79416509
Progressive multiple sclerosis	54.29	14.69	21	39249	1196	79703922
Nocturia	53.01	14.69	48	39222	13633	79691485
Cystitis	52.95	14.69	94	39176	52638	79652480
Diarrhoea	52.72	14.69	239	39031	880250	78824868
Product use issue	52.24	14.69	19	39251	209803	79495315
Haemoglobin urine present	51.75	14.69	19	39251	936	79704182
Loss of control of legs	50.85	14.69	23	39247	1942	79703176
Urine abnormality	48.94	14.69	37	39233	8182	79696936
Pancytopenia	48.64	14.69	11	39259	165734	79539384
Muscle spasms	48.29	14.69	192	39078	174538	79530580
Nitrite urine present	47.40	14.69	19	39251	1190	79703928
Primary progressive multiple sclerosis	47.21	14.69	11	39259	102	79705016
Paraparesis	46.93	14.69	27	39243	3776	79701342
Blood thyroid stimulating hormone decreased	46.20	14.69	31	39239	5685	79699433
Walking aid user	46.14	14.69	39	39231	10109	79695009
Ankle fracture	46.05	14.69	49	39221	16920	79688198
Lower respiratory tract infection	45.96	14.69	5	39265	129215	79575903
Drug intolerance	45.42	14.69	38	39232	264081	79441037
Bacterial test positive	45.39	14.69	34	39236	7415	79697703
Invasive ductal breast carcinoma	45.34	14.69	31	39239	5861	79699257
Generalised tonic-clonic seizure	45.02	14.69	79	39191	43831	79661287
Treatment failure	44.94	14.69	14	39256	170472	79534646
Hip fracture	44.85	14.69	65	39205	30696	79674422
Tremor	44.70	14.69	184	39086	169899	79535219
Feeling abnormal	44.04	14.69	175	39095	159024	79546094
Magnetic resonance imaging abnormal	43.87	14.69	25	39245	3434	79701684
Temperature intolerance	43.52	14.69	37	39233	9668	79695450
Lymphocyte count abnormal	43.41	14.69	19	39251	1484	79703634
Thrombocytopenia	43.39	14.69	40	39230	265219	79439899
Escherichia test positive	43.12	14.69	24	39246	3151	79701967
Hemiparesis	43.08	14.69	67	39203	33666	79671452
Gastrointestinal haemorrhage	42.95	14.69	10	39260	147709	79557409
Urinary tract infection bacterial	42.79	14.69	31	39239	6425	79698693
Glycosylated haemoglobin increased	42.62	14.69	50	39220	19210	79685908
Musculoskeletal disorder	41.47	14.69	52	39218	21396	79683722
Drug hypersensitivity	41.21	14.69	52	39218	298864	79406254
Urinary tract infection pseudomonal	40.15	14.69	19	39251	1779	79703339
Optic neuritis	40.06	14.69	35	39235	9485	79695633
Product dose omission issue	40.01	14.69	233	39037	247304	79457814
Pericarditis	39.84	14.69	3	39267	104233	79600885
Infusion related reaction	39.73	14.69	33	39237	230204	79474914
Hand deformity	39.69	14.69	3	39267	103916	79601202
Multiple organ dysfunction syndrome	39.52	14.69	6	39264	120240	79584878
Immune reconstitution inflammatory syndrome	39.40	14.69	41	39229	13800	79691318
Blood immunoglobulin M decreased	39.28	14.69	17	39253	1292	79703826
B-lymphocyte count abnormal	38.77	14.69	9	39261	82	79705036
Epilepsy	38.68	14.69	71	39199	40789	79664329
Decreased appetite	38.09	14.69	69	39201	342349	79362769
Abdominal pain	37.80	14.69	85	39185	389484	79315634
Erectile dysfunction	37.43	14.69	41	39229	14623	79690495
Urine odour abnormal	36.82	14.69	28	39242	6245	79698873
General symptom	36.74	14.69	20	39250	2514	79702604
Acute disseminated encephalomyelitis	36.10	14.69	11	39259	302	79704816
Platelet count decreased	36.00	14.69	26	39244	194638	79510480
Extra dose administered	35.54	14.69	31	39239	8384	79696734
Urine ketone body present	35.38	14.69	22	39248	3543	79701575
Hyponatraemia	35.24	14.69	22	39248	177826	79527292
Neutrophil percentage increased	34.50	14.69	24	39246	4665	79700453
Protein urine present	34.40	14.69	33	39237	10079	79695039
Glossodynia	34.31	14.69	5	39265	103332	79601786
Breast cancer	33.63	14.69	60	39210	33721	79671397
Urosepsis	32.97	14.69	52	39218	26443	79678675
Hyperkalaemia	32.75	14.69	8	39262	114390	79590728
Stomatitis	32.19	14.69	16	39254	146741	79558377
Hypoxia	32.05	14.69	6	39264	103237	79601881
Renal failure	32.04	14.69	31	39239	200937	79504181
Pleural effusion	31.61	14.69	16	39254	145246	79559872
Rash	31.60	14.69	162	39108	578196	79126922
Sensory disturbance	31.48	14.69	38	39232	15039	79690079
Exposure during pregnancy	31.13	14.69	6	39264	101126	79603992
Cystitis klebsiella	31.12	14.69	10	39260	328	79704790
Respiratory failure	31.12	14.69	26	39244	180885	79524233
Muscle tightness	31.06	14.69	35	39235	12879	79692239
Cognitive disorder	30.94	14.69	90	39180	69836	79635282
Cardiac failure	30.89	14.69	19	39251	154823	79550295
Pneumonia	30.66	14.69	195	39075	660051	79045067
Weight increased	29.86	14.69	57	39213	277329	79427789
Metabolic acidosis	29.84	14.69	3	39267	82526	79622592
Haematochezia	29.67	14.69	4	39266	87641	79617477
General physical health deterioration	29.25	14.69	57	39213	275181	79429937
Cardiac failure congestive	29.07	14.69	17	39253	142385	79562733
Drug ineffective	28.71	14.69	715	38555	1080198	78624920
Burning sensation	28.42	14.69	78	39192	58554	79646564
Oxygen saturation decreased	28.40	14.69	14	39256	129033	79576085
International normalised ratio increased	28.36	14.69	4	39266	84717	79620401
Vitamin D deficiency	28.21	14.69	35	39235	14244	79690874
Cardiac arrest	28.07	14.69	26	39244	172070	79533048
Arthralgia	28.03	14.69	166	39104	571637	79133481
Rhabdomyolysis	28.02	14.69	8	39262	103123	79601995
Back pain	27.97	14.69	250	39020	303930	79401188
Decreased vibratory sense	27.86	14.69	11	39259	662	79704456
Asthma	27.76	14.69	16	39254	135079	79570039
Coordination abnormal	27.33	14.69	38	39232	17274	79687844
Urinary tract infection enterococcal	26.94	14.69	18	39252	3277	79701841
Sinusitis	26.94	14.69	34	39236	195467	79509651
Vomiting	26.80	14.69	205	39065	665623	79039495
Wheelchair user	26.72	14.69	23	39247	6109	79699009
Contraindicated product administered	26.65	14.69	23	39247	157515	79547603
CD8 lymphocyte percentage decreased	26.47	14.69	4	39266	0	79705118
Vitamin D decreased	26.24	14.69	28	39242	9697	79695421
Limb discomfort	26.09	14.69	53	39217	32797	79672321
Urinary sediment present	26.06	14.69	16	39254	2519	79702599
CD8 lymphocytes increased	26.01	14.69	6	39264	53	79705065
Monocyte percentage increased	25.88	14.69	15	39255	2126	79702992
Hypoglycaemia	25.61	14.69	9	39261	101585	79603533
Arthropathy	25.24	14.69	30	39240	177081	79528037
Neutrophil count increased	25.24	14.69	49	39221	29347	79675771
Decreased interest	25.07	14.69	18	39252	3679	79701439
Swelling	24.68	14.69	43	39227	216668	79488450
Pyrexia	24.56	14.69	215	39055	678494	79026624
Overdose	24.39	14.69	33	39237	184173	79520945
Invasive lobular breast carcinoma	23.87	14.69	10	39260	701	79704417
Therapeutic product effect incomplete	23.57	14.69	21	39249	141624	79563494
Cardio-respiratory arrest	23.54	14.69	12	39258	108498	79596620
Urinary retention	23.26	14.69	71	39199	56559	79648559
Hepatic function abnormal	23.23	14.69	4	39266	73103	79632015
Product use in unapproved indication	23.15	14.69	56	39214	250303	79454815
Human papilloma virus test positive	22.96	14.69	9	39261	531	79704587
Visual impairment	22.88	14.69	98	39172	92033	79613085
Headache	22.84	14.69	450	38820	653322	79051796
Vitamin B12 abnormal	22.81	14.69	6	39264	95	79705023
Prescribed underdose	22.71	14.69	47	39223	29467	79675651
Lymphocyte percentage abnormal	22.70	14.69	5	39265	35	79705083
Urinary tract disorder	22.62	14.69	17	39253	3725	79701393
Red blood cell count abnormal	22.55	14.69	12	39258	1441	79703677
Ascites	22.19	14.69	5	39265	75557	79629561
Speech disorder	22.12	14.69	68	39202	54377	79650741
Fibromyalgia	21.62	14.69	3	39267	64337	79640781
Herpes zoster	21.58	14.69	97	39173	92986	79612132
Urinary tract infection staphylococcal	21.45	14.69	10	39260	905	79704213
Intentional product use issue	21.43	14.69	26	39244	152086	79553032
Lymphocyte count increased	21.40	14.69	20	39250	5912	79699206
Expanded disability status scale score increased	21.20	14.69	9	39261	652	79704466
Intentional overdose	21.13	14.69	13	39257	105947	79599171
Tongue biting	20.83	14.69	13	39257	2108	79703010
Fear of falling	20.77	14.69	9	39261	686	79704432
Maternal exposure during pregnancy	20.69	14.69	22	39248	136516	79568602
Disease progression	20.61	14.69	37	39233	184325	79520793
Mean cell haemoglobin increased	20.58	14.69	17	39253	4268	79700850
Rectal haemorrhage	20.58	14.69	6	39264	76294	79628824
Glucose urine present	20.43	14.69	12	39258	1744	79703374
B-lymphocyte count increased	20.42	14.69	6	39264	145	79704973
Urinary sediment abnormal	20.42	14.69	6	39264	145	79704973
Pulmonary oedema	20.30	14.69	9	39261	88245	79616873
Spinal cord injury cauda equina	20.15	14.69	6	39264	152	79704966
Blood urine present	20.14	14.69	37	39233	21260	79683858
Vitamin D abnormal	20.11	14.69	6	39264	153	79704965
CD4 lymphocyte percentage decreased	20.04	14.69	4	39266	16	79705102
Intervertebral disc protrusion	19.82	14.69	39	39231	23582	79681536
Therapy interrupted	19.68	14.69	46	39224	31295	79673823
Blood thyroid stimulating hormone increased	19.51	14.69	24	39246	9684	79695434
Dysgraphia	19.38	14.69	16	39254	4016	79701102
Vitamin B6 deficiency	19.18	14.69	7	39263	339	79704779
Fatigue	19.00	14.69	595	38675	929132	78775986
Somatosensory evoked potentials abnormal	18.76	14.69	6	39264	194	79704924
Angioedema	18.72	14.69	7	39263	76028	79629090
Bacterial test	18.70	14.69	10	39260	1213	79703905
Anaphylactic reaction	18.55	14.69	9	39261	83734	79621384
Nephrolithiasis	18.43	14.69	63	39207	53228	79651890
Feeling hot	18.42	14.69	68	39202	59666	79645452
Septic shock	18.37	14.69	20	39250	122781	79582337
Hypersensitivity	18.22	14.69	67	39203	262172	79442946
Crystal urine present	18.14	14.69	12	39258	2148	79702970
Rash maculo-papular	17.96	14.69	3	39267	56075	79649043
Citrobacter infection	17.90	14.69	9	39261	961	79704157
Hypokinesia	17.88	14.69	33	39237	19027	79686091
Urobilinogen urine increased	17.69	14.69	8	39262	675	79704443
Skin laceration	17.63	14.69	42	39228	28920	79676198
Proteus test positive	17.48	14.69	7	39263	437	79704681
Wheezing	17.45	14.69	19	39251	116645	79588473
Tibia fracture	17.30	14.69	17	39253	5344	79699774
C-reactive protein increased	17.19	14.69	23	39247	129004	79576114
Neuropathy peripheral	17.05	14.69	27	39243	141278	79563840
Focal dyscognitive seizures	17.01	14.69	14	39256	3498	79701620
Hypokalaemia	16.93	14.69	28	39242	144012	79561106
Dyspnoea exertional	16.93	14.69	11	39259	87062	79618056
Urine uric acid decreased	16.85	14.69	5	39265	125	79704993
Blood pressure fluctuation	16.83	14.69	6	39264	67139	79637979
Red blood cell count increased	16.77	14.69	15	39255	4193	79700925
Hepatic enzyme increased	16.76	14.69	41	39229	182569	79522549
Infection	16.63	14.69	62	39208	241650	79463468
Incontinence	16.53	14.69	27	39243	14137	79690981
Lactic acidosis	16.46	14.69	7	39263	70352	79634766
White matter lesion	16.42	14.69	11	39259	2011	79703107
Insurance issue	16.35	14.69	17	39253	5716	79699402
Haematemesis	16.30	14.69	3	39267	52261	79652857
Blister	16.22	14.69	21	39249	119455	79585663
Wound	16.21	14.69	20	39250	116159	79588959
Pneumonitis	16.02	14.69	5	39265	60855	79644263
Intentional product misuse	15.96	14.69	14	39256	95151	79609967
Hepatotoxicity	15.90	14.69	3	39267	51349	79653769
Frustration tolerance decreased	15.81	14.69	19	39251	7483	79697635
CD4 lymphocytes abnormal	15.80	14.69	4	39266	54	79705064
Haemorrhage	15.78	14.69	13	39257	91105	79614013
Foot fracture	15.75	14.69	34	39236	21947	79683171
Red blood cell count decreased	15.71	14.69	63	39207	57450	79647668
Diplopia	15.70	14.69	44	39226	33422	79671696
Urine cannabinoids increased	15.70	14.69	3	39267	9	79705109
Wrist fracture	15.67	14.69	24	39246	11897	79693221
Lower limb fracture	15.60	14.69	35	39235	23180	79681938
Electrocardiogram QT prolonged	15.52	14.69	13	39257	90373	79614745
Dysdiadochokinesis	15.52	14.69	6	39264	341	79704777
Coma	15.49	14.69	16	39254	100633	79604485
Sensory loss	15.48	14.69	25	39245	12966	79692152
Therapeutic response changed	15.42	14.69	9	39261	1292	79703826
Mean cell haemoglobin decreased	15.19	14.69	17	39253	6207	79698911
Urinary tract obstruction	15.18	14.69	15	39255	4750	79700368
Blood pressure systolic increased	15.14	14.69	7	39263	66979	79638139
Haematocrit decreased	15.05	14.69	65	39205	61247	79643871
Streptococcal urinary tract infection	14.89	14.69	6	39264	381	79704737
Stress	14.88	14.69	78	39192	79534	79625584
Irritable bowel syndrome	14.87	14.69	6	39264	62235	79642883
Chronic kidney disease	14.82	14.69	7	39263	66147	79638971
Renal impairment	14.81	14.69	35	39235	157748	79547370
Plasma cell myeloma	14.71	14.69	4	39266	53255	79651863

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N07XX07	NERVOUS SYSTEM OTHER NERVOUS SYSTEM DRUGS OTHER NERVOUS SYSTEM DRUGS Other nervous system drugs
FDA MoA	N0000175448	Potassium Channel Antagonists
FDA EPC	N0000192795	Potassium Channel Blocker
CHEBI has role	CHEBI:33289	avicides
CHEBI has role	CHEBI:71031	orphan drugs
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D026902	Potassium Channel Blockers

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Multiple sclerosis	indication	24700007	DOID:2377
Seizure disorder	contraindication	128613002
Impaired renal function disorder	contraindication	197663003

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.58	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Voltage-gated potassium channel	Ion channel	O43525 O43526 O95259 P16389 P17658 P22001 P22459 P22460 P48547 P51787 P56696 Q03721 Q09470 Q12809 Q14003 Q14721 Q16322 Q6PIU1 Q8NCM2 Q8TAE7 Q8TDN1 Q8TDN2 Q92953 Q96KK3 Q96L42 Q96PR1 Q96RP8 Q9BQ31 Q9H252 Q9H3M0 Q9NR82 Q9NS40 Q9NSA2 Q9NZV8 Q9UIX4 Q9UJ96 Q9UK17 Q9ULD8 Q9ULS6 Q9UQ05	KCNQ3_HUMAN KCNQ2_HUMAN KCNH1_HUMAN KCNA2_HUMAN KCNA6_HUMAN KCNA3_HUMAN KCNA4_HUMAN KCNA5_HUMAN KCNC1_HUMAN KCNQ1_HUMAN KCNQ4_HUMAN KCNC4_HUMAN KCNA1_HUMAN KCNH2_HUMAN KCNC3_HUMAN KCNB1_HUMAN KCA10_HUMAN KCNV1_HUMAN KCNH5_HUMAN KCNG3_HUMAN KCNG4_HUMAN KCNV2_HUMAN KCNB2_HUMAN KCNS1_HUMAN KCNH8_HUMAN KCNC2_HUMAN KCNA7_HUMAN KCNS3_HUMAN KCNH6_HUMAN KCNF1_HUMAN KCNQ5_HUMAN KCNH7_HUMAN KCND1_HUMAN KCND2_HUMAN KCNG1_HUMAN KCNG2_HUMAN KCND3_HUMAN KCNH3_HUMAN KCNS2_HUMAN KCNH4_HUMAN	BLOCKER	IC50	4.05		CHEMBL	CHEMBL
Potassium voltage-gated channel subfamily C member 1	Ion channel		KCNC1_MOUSE	BLOCKER	IC50	4.50		IUPHAR
Potassium voltage-gated channel subfamily C member 2	Ion channel		KCNC2_RAT	BLOCKER	IC50	4.60		IUPHAR

External reference:

ID	Source
4029704	VUID
N0000180628	NUI
D04127	KEGG_DRUG
4025700	VANDF
4025705	VANDF
4029704	VANDF
C0000477	UMLSCUI
CHEBI:34385	CHEBI
4AP	PDB_CHEM_ID
CHEMBL284348	ChEMBL_ID
DB06637	DRUGBANK_ID
2416	IUPHAR_LIGAND_ID
1727	PUBCHEM_CID
897018	RXNORM
170373	MMSL
26967	MMSL
NOCODE	MMSL
d07546	MMSL
006829	NDDF
413355004	SNOMEDCT_US
80994002	SNOMEDCT_US
D015761	MESH_DESCRIPTOR_UI
7283	INN_ID
BH3B64OKL9	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Dalfampridine	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0479	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	27 sections
dalfampridine	HUMAN PRESCRIPTION DRUG LABEL	1	0378-0509	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	NDA authorized generic	27 sections
dalfampridine	HUMAN PRESCRIPTION DRUG LABEL	1	0378-4504	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	29 sections
Dalfampridine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-2533	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	27 sections
AMPYRA	HUMAN PRESCRIPTION DRUG LABEL	1	10144-427	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	NDA	27 sections
AMPYRA	HUMAN PRESCRIPTION DRUG LABEL	1	10144-427	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	NDA	27 sections
Dalfampridine	HUMAN PRESCRIPTION DRUG LABEL	1	16729-292	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	29 sections
Dalfampridine	HUMAN PRESCRIPTION DRUG LABEL	1	16729-292	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	29 sections
Dalfampridine	HUMAN PRESCRIPTION DRUG LABEL	1	16729-292	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	29 sections
DALFAMPRIDINE	HUMAN PRESCRIPTION DRUG LABEL	1	42571-275	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	26 sections
DALFAMPRIDINE	HUMAN PRESCRIPTION DRUG LABEL	1	42571-275	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	26 sections
Dalfampridine	HUMAN PRESCRIPTION DRUG LABEL	1	51407-246	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	29 sections
Dalfampridine	HUMAN PRESCRIPTION DRUG LABEL	1	51407-246	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	29 sections
Dalfampridine	HUMAN PRESCRIPTION DRUG LABEL	1	51407-246	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	29 sections
Dalfampridine	Human Prescription Drug Label	1	62756-429	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	27 sections
Dalfampridine	HUMAN PRESCRIPTION DRUG LABEL	1	63629-9450	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	26 sections
Dalfampridine	HUMAN PRESCRIPTION DRUG LABEL	1	63629-9450	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	26 sections
DALFAMPRIDINE	Human Prescription Drug Label	1	65862-863	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	26 sections
Dalfampridine	Human Prescription Drug Label	1	67877-444	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	26 sections
Dalfampridine	Human Prescription Drug Label	1	67877-444	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	26 sections
Dalfampridine	Human Prescription Drug Label	1	67877-444	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	26 sections